MediGene and Triton Pharma Sign Partnership Agreement for the Commercialization of Veregen in Canada

21-Apr-2011 - Canada

The biotech company MediGene AG has signed an exclusive license and supply agreement with the Canadian company Triton Pharma Inc. for the supply and commercialization of Veregen® ointment for the treatment of genital warts in Canada. Triton will be responsible for the drug approval procedure in Canada. MediGene is entitled to successive payments totaling up to 2.1 million euros, due upon the achievement of set milestones, and will obtain royalties on the sales revenue generated with Veregen® in the form of a double-digit percentage share.

"We are happy that we have found the ideal partner for the commercialization of Veregen® ointment in Canada. With this agreement and our existing partnerships with Nycomed and Pierre Fabre, we are now able to serve the entire North and Central American market." commented Dr. Frank Mathias, Chief Executive Officer of MediGene AG.

MediGene has already entered into several marketing partnerships for Veregen®, e.g. with Nycomed, Inc. for the USA, with Abbott for Germany, Austria, and Switzerland, with Laboratoires Expanscience for France, and with a number of other partners across Europe, America, and Asia. MediGene is planning to continue this global licensing strategy.

Veregen® is currently available on the US, German, and Austrian markets. A second wave of marketing applications within the European mutual recognition procedure is planned, with Germany serving as the reference state in this process.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances